Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oportuzumab monatox
- Development stage
- Discontinued
- Lead developer
- Sesen Bio
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravesical
01
Overview
Oportuzumab monatox is an investigational fusion protein immunotoxin designed for the treatment of non-muscle invasive bladder cancer (NMIBC), particularly in patients unresponsive to Bacillus Calmette-Guérin (BCG) therapy. The drug consists of a humanized single-chain variable fragment (scFv) monoclonal antibody targeting the epithelial cell adhesion molecule (EpCAM), which is highly expressed on carcinoma cells of epithelial origin. This antibody fragment is conjugated to a truncated form of Pseudomonas exotoxin A. Upon binding to EpCAM-positive tumor cells, the fusion protein is internalized and releases the toxin moiety into the cytosol, where it inactivates elongation factor 2 through ADP ribosylation—resulting in inhibition of protein synthesis and induction of apoptosis in target cells. Oportuzumab monatox has been developed for locoregional delivery via intravesical administration to maximize local concentration and minimize systemic exposure[1][5][6][8]. The drug was originally developed by Viventia Bio and later by Sesen Bio following acquisition[3].
- Brand names
- VicineumViciniumVysyneum
- Other names
- oportuzumab monatox-qqrs
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on oportuzumab monatox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oportuzumab monatox.